Lo mejor del Congreso Virtual ACC/WCC 2020 / The best of the 2020 ACC/WCC Virtual Congress / O melhor do Congresso Virtual ACC/WCC 2020

RESUMEN

Resumen La pandemia generada por el SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus) ha constituido un desafío mundial. En momentos de dificultad como los que se han presentado recientemente, es aún más necesaria la investigación para avanzar en el diagnóstico y tratamiento de las diferentes patologías. Utilizando el amplio desarrollo de los medios de comunicación, este año el Congreso del Colegio Americano de Cardiología (ACC por su sigla en inglés) se celebró del 28 al 30 de marzo en un formato virtual, permitiendo a profesionales de todo el mundo acceder a múltiples actividades científicas con el mismo nivel de excelencia que en las sesiones presenciales. Realizaremos un breve resumen de alguno de los principales trabajos científicos presentados - Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention TAILOR-PCI. - Rivaroxaban in Peripheral Artery Disease after Revascularization VOYAGER PAD trial. - Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction VICTORIA Study Group. - The Evolut Low Risk Bicuspid Study. - PARTNER 3. Two-year clinical and echocardiographic outcomes. - Ticagrelor with and without Aspirin in Acute Coronary Syndrome After PCI the TICO Trial - Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer Caravaggio trial. - Ten-year Outcomes After Drug-eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease Extended Follow Up of the PRECOMBAT Trial. - Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation POPular TAVI.

ABSTRACT

Summary The SARS-CoV-2 pandemic has been a global challenge. In times of difficulty such as those that have recently arisen, research is even more necessary to advance in the diagnosis and treatment of different pathologies. Using the extensive development of the media, this year the American Congress of Cardiology was held from March 28 to 30 in a virtual format, allowing professionals from around the world to access multiple scientific activities with the same level of excellence as in face-to-face sessions. We will make a brief summary of some of the main scientific papers presented - Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention TAILOR-PCI. - Rivaroxaban in Peripheral Artery Disease after Revascularization VOYAGER PAD trial. - Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction VICTORIA Study Group. - The Evolut Low Risk Bicuspid Study. - PARTNER 3. Two-year clinical and echocardiographic outcomes. - Ticagrelor with and without Aspirin in Acute Coronary Syndrome After PCI the TICO Trial. - Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer Caravaggio trial. - Ten-year Outcomes After Drug-eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease Extended Follow Up of the PRECOMBAT Trial. - Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation POPular TAVI.

RESUMO

Resumo A pandemia de SARS-CoV-2 tem sido um desafio global. Em tempos de dificuldade como os que surgiram recentemente, a pesquisa é ainda mais necessária para avançar no diagnóstico e tratamento de diferentes patologias. Utilizando o amplo desenvolvimento da mídia, este ano o Congresso Americano de Cardiologia foi realizado de 28 ao 30 de março em um formato virtual, permitindo que profissionais de todo o mundo acessassem diversas atividades científicas com o mesmo nível de excelência que nas sessões presenciais. Faremos um breve resumo de alguns dos principais trabalhos científicos apresentados - Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention TAILOR - PCI. - Rivaroxaban in Peripheral Artery Disease after Revascularization VOYAGER PAD trial. - Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction VICTORIA Study Group. - The Evolut Low Risk Bicuspid Study. - PARTNER 3. Two-year clinical and echocardiographic outcomes. - Ticagrelor with and without Aspirin in Acute Coronary Syndrome After PCI the TICO Trial. - Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer Caravaggio trial. - Ten-year Outcomes After Drug-eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease Extended Follow Up of the PRECOMBAT Trial. - Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation POPular TAVI.